share_log

Pyxis Oncology Announces FDA Clearance Of Two IND Applications

Benzinga Real-time News ·  Dec 1, 2022 06:48

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate

Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity in patients with select solid tumors

Dual IND clearances represent achievement of significant 2022 milestones and executional pipeline advancement

Cash runway extended into first half 2025

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment